Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz


1. 6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3h),2'-(2h)pyran)-3',4',5'-triol
2. Apleway
3. Csg452
4. Deberza
5. Tofogliflozin Anhydrous
6. Tofogliflozin Hydrate
1. 903565-83-3
2. Csg 452
3. Tofogliflozin [inn]
4. Tofogliflozin Anhydrous
5. Csg-452
6. (3s,3'r,4's,5's,6'r)-5-[(4-ethylphenyl)methyl]-6'-(hydroxymethyl)spiro[1h-2-benzofuran-3,2'-oxane]-3',4',5'-triol
7. R-7201
8. 903565-83-3 (free)
9. 554245w62t
10. (1s,3'r,4's,5's,6'r)-6-(4-ethylbenzyl)-6'-(hydroxymethyl)-3',4',5',6'-tetrahydro-3h-spiro[isobenzofuran-1,2'-pyran]-3',4',5'-triol
11. Spiro(isobenzofuran-1(3h),2'-(2h)pyran)-3',4',5'-triol,6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)-,(1s,3'r,4's,5's,6'r)-
12. Apleway
13. Deberza
14. Tofogliflozin Anyhydrous
15. Ro4998452
16. Ro-4998452
17. Unii-554245w62t
18. Tofogliflozin [mi]
19. Ec 619-989-0
20. Schembl903156
21. Tofogliflozin [who-dd]
22. Gtpl9395
23. Chembl2110731
24. Csg452;csg-452
25. Dtxsid90238097
26. Chebi:136041
27. Bdbm50396779
28. Zinc35826342
29. Db11824
30. Compound 16d [pmid: 22889351]
31. Ncgc00485920-01
32. Ac-31468
33. Q27261271
34. (1s,3'r,4's,5's,6'r)-6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)-spiro(isobenzofuran-1(3h), 2'-(2h)pyran)-3',4',5'-triol
35. (1s,3'r,4's,5's,6'r)-6-((4-ethylphenyl)methyl)-6'-(hydroxymethyl)-3',4',5',6'-tetrahydro-3h-spiro(2-benzofuran-1,2'-pyran)-3',4',5'-triol
| Molecular Weight | 386.4 g/mol |
|---|---|
| Molecular Formula | C22H26O6 |
| XLogP3 | 1.5 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Exact Mass | 386.17293854 g/mol |
| Monoisotopic Mass | 386.17293854 g/mol |
| Topological Polar Surface Area | 99.4 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 521 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Sodium-Glucose Transporter 2 Inhibitors
Compounds that inhibit SODIUM-GLUCOSE TRANSPORTER 2. They lower blood sugar by preventing the reabsorption of glucose by the kidney and are used in the treatment of TYPE 2 DIABETES MELLITUS. (See all compounds classified as Sodium-Glucose Transporter 2 Inhibitors.)
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Details:
Tofogliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.
Lead Product(s): Tofogliflozin,Insulin
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Kowa Company
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 25, 2014
Lead Product(s) : Tofogliflozin,Insulin
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Kowa Company
Deal Size : Inapplicable
Deal Type : Inapplicable
TOFO Insulin Combination Trial
Details : Tofogliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 25, 2014
Details:
K-001 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): K-001,Pemafibrate,Tofogliflozin
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 10, 2023

Lead Product(s) : K-001,Pemafibrate,Tofogliflozin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : K-001 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 10, 2023

Details:
Tofogliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.
Lead Product(s): Tofogliflozin,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Kowa Company
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 22, 2022

Lead Product(s) : Tofogliflozin,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Kowa Company
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tofogliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 22, 2022

Details:
K-877 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Lead Product(s): Pemafibrate,Tofogliflozin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 14, 2022

Lead Product(s) : Pemafibrate,Tofogliflozin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : K-877 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 14, 2022

Details:
K-877 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Pemafibrate,Tofogliflozin
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 23, 2020

Lead Product(s) : Pemafibrate,Tofogliflozin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetic Drug-Drug Interaction Study Between K-877 and CSG452 in Healthy Adult Volunteers
Details : K-877 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 23, 2020

Details:
Tofogliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Lead Product(s): Tofogliflozin,Glimepiride
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Kowa Company
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 07, 2016

Lead Product(s) : Tofogliflozin,Glimepiride
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Kowa Company
Deal Size : Inapplicable
Deal Type : Inapplicable
SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD
Details : Tofogliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 07, 2016

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Tofogliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.
Lead Product(s): Tofogliflozin,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Sanofi
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 02, 2015

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tofogliflozin,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Tofogliflozin GLP-1 Analogue Combination Trial
Details : Tofogliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 02, 2015

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
RO4998452 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.
Lead Product(s): Tofogliflozin,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 07, 2010

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tofogliflozin,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes
Details : RO4998452 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 07, 2010

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Reply
23 Nov 2022
Reply
03 Feb 2021

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
ABOUT THIS PAGE
98
PharmaCompass offers a list of Tofogliflozin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Tofogliflozin manufacturer or Tofogliflozin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tofogliflozin manufacturer or Tofogliflozin supplier.
A Tofogliflozin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tofogliflozin, including repackagers and relabelers. The FDA regulates Tofogliflozin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tofogliflozin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tofogliflozin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Tofogliflozin supplier is an individual or a company that provides Tofogliflozin active pharmaceutical ingredient (API) or Tofogliflozin finished formulations upon request. The Tofogliflozin suppliers may include Tofogliflozin API manufacturers, exporters, distributors and traders.
click here to find a list of Tofogliflozin suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
Tofogliflozin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tofogliflozin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Tofogliflozin GMP manufacturer or Tofogliflozin GMP API supplier for your needs.
A Tofogliflozin CoA (Certificate of Analysis) is a formal document that attests to Tofogliflozin's compliance with Tofogliflozin specifications and serves as a tool for batch-level quality control.
Tofogliflozin CoA mostly includes findings from lab analyses of a specific batch. For each Tofogliflozin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tofogliflozin may be tested according to a variety of international standards, such as European Pharmacopoeia (Tofogliflozin EP), Tofogliflozin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tofogliflozin USP).